These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 1987300)
21. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1. Kabel AM; Omar MS; Alhadhrami A; Alharthi SS; Alrobaian MM Physiol Behav; 2018 May; 188():108-118. PubMed ID: 29410018 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242 [TBL] [Abstract][Full Text] [Related]
23. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
25. Levodopa with benserazide or carbidopa in Parkinson disease. Rinne UK; Mölsä P Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221 [TBL] [Abstract][Full Text] [Related]
26. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Peppe A; Dambrosia JM; Chase TN Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213 [No Abstract] [Full Text] [Related]
27. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Smith LA; Gordin A; Jenner P; Marsden CD Mov Disord; 1997 Nov; 12(6):935-45. PubMed ID: 9399218 [TBL] [Abstract][Full Text] [Related]
28. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197 [TBL] [Abstract][Full Text] [Related]
29. Combined use of benserazide and carbidopa in Parkinson's disease. Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015 [TBL] [Abstract][Full Text] [Related]
30. Hypotensive effect of long-term levodopa in patients with Parkinson's disease. Iwasaki S; Hamaguchi K; Iwasaki A; Takakusagi M; Narabayashi Y Eur Neurol; 1990; 30(4):194-9. PubMed ID: 2209672 [TBL] [Abstract][Full Text] [Related]
32. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report. Savery F Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863 [No Abstract] [Full Text] [Related]
33. Neuroleptic malignant syndrome associated with the use of carbidopa/levodopa for dystonia in persons with cerebral palsy. Perry D; Birthi P; Salles S; McDowell S PM R; 2012 May; 4(5):383-4. PubMed ID: 22613365 [No Abstract] [Full Text] [Related]
34. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease. Celesia GG; Wanamaker WM Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661 [TBL] [Abstract][Full Text] [Related]
35. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234 [TBL] [Abstract][Full Text] [Related]
36. Dietary influence of tyrosine and phenylalanine on the response of B16 melanoma to carbidopa-levodopa methyl ester chemotherapy. Meadows GG; Pierson HF; Abdallah RM; Desai PR Cancer Res; 1982 Aug; 42(8):3056-63. PubMed ID: 7093952 [No Abstract] [Full Text] [Related]
37. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Fung VS; Herawati L; Wan Y; ; Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551 [TBL] [Abstract][Full Text] [Related]
38. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa. Stewart RM; Miller S; Gunder M Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350 [TBL] [Abstract][Full Text] [Related]